CoChat

Identification of cisplatin‐resistance related genes in head and neck squamous cell carcinoma

Open access
Yamano, Yukio, Uzawa, Katsuhiro, Saito, Kengo, Nakashima, Dai, Kasamatsu, Atsushi, Koike, Hirofumi, Kouzu, Yukinao, Shinozuka, Keiji, Nakatani, Ken, Negoro, Kenji, Fujita, Shigeyuki, Tanzawa, Hideki · 2010 · International Journal of Cancer
Cited by 91

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Resistance to cisplatin is a major obstacle to successful treatment of head and neck squamous cell carcinoma (HNSCC). To investigate the molecular mechanism of this resistance, we compared the gene expression profiles between the cisplatin‐sensitive SCC cell lines (Sa‐3, H‐1 and KB) and the cisplatin‐resistant cell lines established from them (Sa‐3R, H‐1R and KB‐R) using Affymetrix U133 Plus 2.0 microarray. We identified 199 genes differentially expressed in each group. To identify important functional networks and ontologies to cisplatin resistance, the 199 genes were analyzed using the Ingenuity Pathway Analysis Tool. Fifty‐one of these genes were mapped to genetic networks, and we validated the top‐10 upregulated genes by real‐time reverse transcriptase‐polymerase chain reaction. Five novel genes, LUM, PDE3B, PDGF‐C, NRG1 and PKD2, showed excellent concordance with the microarray data. In 48 patients with oral SCC (OSCC), positive immunohistochemical staining for the five genes correlated with chemoresistance to cisplatin‐based combination chemotherapy. In addition, the expression of the five genes predicted the patient outcomes with chemotherapy. Furthermore, siRNA‐directed suppressed expression of the five genes resulted in enhanced susceptibility to cisplatin‐mediated apoptosis. These results suggested that these five novel genes have great potential for predicting the efficacy of cisplatin‐based chemotherapy against OSCC. Global gene analysis of cisplatin‐resistant cell lines may provide new insights into the mechanisms underlying clinical cisplatin resistance and improve the efficacy of chemotherapy for human HNSCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.24704

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Mechanisms of Cancer Drug Resistance

    Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 10×

    “In addition, several microarray studies have been performed to identify genes with altered expression in HNSCC.2,14 From these studies, numerous genes have been associated with the development and progression of head and neck cancer, some of which will be used as novel chemotherapeutic targets to treat or prevent HNSC…”
    BackgroundInfluential
  • Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy

    Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., Bast, R. C., Stec, J., Iartchouk, N., Smith, D. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1673 · Cited by 141 · cited 1×

    “identified a gene expression profile in acute lymphoblastic leukemia and ovarian cancer that contained a paucity of transcripts commonly implicated in resistance.(15,16) However, we have identified some drug resistant related genes; ABCC1,(17,18) AKR1C1,(19,20) AKR1C2,(19,20) CYP1B1,(21) SGPP1,(22) and CDKN2A(23) (Sup…”
    Background

Cited by

See all 91

Metadata

Authors
Yamano, Y., Uzawa, K., Saito, K., Nakashima, D., Kasamatsu, A., Koike, H., Kouzu, Y., Shinozuka, K., Nakatani, K., Negoro, K., Fujita, S., & Tanzawa, H.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2009-08-24
Volume
126
Issue
2
Pages
437-449
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2022152336
Cited by
91
References
2
FWCI
3.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.